Akoustis Technologies - AKTS Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akoustis Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKTS shares.
View AKTS analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 1 year target prices for Akoustis Technologies' shares. Their AKTS share price forecasts range from $7.00 to $13.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 95.3% from the stock's current price.
View analysts price targets for AKTS or view top-rated stocks among Wall Street analysts.

Akoustis Technologies' stock was trading at $6.68 at the beginning of 2022. Since then, AKTS shares have decreased by 23.4% and is now trading at $5.12.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 29th 2022.
View our AKTS earnings forecast.

Akoustis Technologies, Inc. (NASDAQ:AKTS) announced its quarterly earnings data on Sunday, October, 31st. The technology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.05. The technology company earned $1.87 million during the quarter, compared to analyst estimates of $1.97 million. Akoustis Technologies had a negative net margin of 430.10% and a negative trailing twelve-month return on equity of 38.00%. The firm's quarterly revenue was up 192.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.23) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akoustis Technologies investors own include Inseego (INSG), NVIDIA (NVDA), Block (SQ), Editas Medicine (EDIT), Marvell Technology (MRVL), Alibaba Group (BABA), Invitae (NVTA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and JD.com (JD).

Akoustis Technologies trades on the NASDAQ under the ticker symbol "AKTS."

Akoustis Technologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Elemental Capital Partners LLC (4.52%), Handelsbanken Fonder AB (3.00%), Ashford Capital Management Inc. (1.84%), Needham Investment Management LLC (1.58%), State Street Corp (1.56%) and Connors Investor Services Inc. (1.05%). Insiders that own company stock include Arthur Geiss, David Aichele, James Michael Mcguire, Jeffrey B Shealy, Jeffrey B Shealy, Jeffrey Mcmahon, Kenneth Boller, Rohan Houlden, Steven Denbaars and Suzanne B Rudy.
View institutional ownership trends.

Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKTS stock can currently be purchased for approximately $5.12.

Akoustis Technologies (NASDAQ:AKTS) has a market capitalization of $286.53 million and generates $6.62 million in revenue each year. The technology company earns $-44,160,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

The company employs 156 workers across the globe.

Akoustis Technologies' mailing address is 9805 NORTHCROSS CENTER COURT SUITE A, HUNTERSVILLE NC, 28078. The official website for the company is www.akoustis.com. The technology company can be reached via phone at (704) 997-5735 or via email at bprag@delmarconsulting.com.